Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (311-320 of 397) with videos related to

Pageof 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesDavid S Hong, Said M Sebti, Robert A Newman, et al.
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Advances in Therapy|July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II TrialRenata Ferrarotto, Luana G Sousa, Yun Qing, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Immunotherapy|August 28, 2015
Strategies for combining immunotherapy with radiation for anticancer therapySteven N Seyedin, Jonathan E Schoenhals, Dean A Lee, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Pageof 40

Showing results (311-320 of 397) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesDavid S Hong, Said M Sebti, Robert A Newman, et al.
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Advances in Therapy|July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II TrialRenata Ferrarotto, Luana G Sousa, Yun Qing, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Immunotherapy|August 28, 2015
Strategies for combining immunotherapy with radiation for anticancer therapySteven N Seyedin, Jonathan E Schoenhals, Dean A Lee, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Pageof 40